首页
登录
职称英语
Last year, when President George W. Bush announced that federal funds could
Last year, when President George W. Bush announced that federal funds could
游客
2025-04-08
11
管理
问题
Last year, when President George W. Bush announced that federal funds could be used to support research on human embryonic stem cells, he mandated that only those cell lines that existed at the time would qualify for such support. More than a year later, it’s becoming increasingly clear that these existing cell lines are inadequate. Unless more are created, the research slowdown may exact a staggering cost in terms of human suffering.
Since this announcement, the US National Institutes of Health has tried to stimulate research on. the existing cell lines with new funding and efforts to streamline the initially cumbersome process of obtaining approved cells. However, whether there are 60 cell lines, as originally stated, or nine, as now appear to be available to NIH-funded investigators, the number is not adequate. Given the genetic diversity within the population, scientists need access to new cell lines if they are to come up with the most effective cell therapies.
The issue is partly one of safety. In conducting research with human participants, we must minimize risks. The most effective cell line might not be the safest. When developing a new medicine, a large number of molecules must be screened to find a balance between effectiveness and safety. The same is true with cells. In the context of cell therapy, it will be important to minimize unwanted immune reactions and inflammation this requires selection from a large number of cell lines to obtain the best match.
It’s clear from experiments with animals that stem-cell therapies can reduce human suffering as Parkinsonian mice have been cured with embryonic stem cells that were programmed to become dopamine-secreting, replacement nerve ceils. Soon, cells induced to make insulin in tissue cultures will be used in attempts to treat diabetic mice. Similar successes have been achieved in animal models of spinal-cord injury, heart failure and other degenerative disorders. We are at a frontier in medicine where tissues will be restored in ways that were not imaginable just a few years ago. The ethical issues raised by human-embryo research are profound. The human costs of restricting this research must be taken into account as well. The cost in dollars of delaying new stem-cell research is difficult to estimate. It might measure in the hundreds of billions of dollars, especially if one adds the lost productivity of individuals who must leave work to care for victims of degenerative disorders.
A less obvious, but real, cost is the damage to the fabric of America’s extraordinary culture of inquiry and technical development in biomedical science. Our universities and teaching hospitals are unparalleled. We attract the very best students, scientists and physicians from around the world. But these institutions are fragile. Research and education play key roles in attracting the best physicians. A crippled research enterprise might add an unbearable stress with long-lasting effects on the entire system. If revolutionary new therapies are delayed or outlawed, we could be set back for years, if not decades.
To steer clear of controversy, some investigators will redirect their research. Others will emigrate to countries where such research is allowed and encouraged. Some will drop out entirely. The pall cast over the science community could extend far beyond stem-cell research. Many therapies have emerged from collaboration between government-sponsored researchers and private enterprise. Few of these discoveries would have emerged if, for instance, recombinant DNA research had been outlawed 30 years ago. We face the same type of decision today with limits placed on human embryonic stem cells. Safeguards will be necessary. But if we do not proceed embracing the values of objective, open, inquiry with complete sharing of methods and results, the field will be left to less rigorous fringe groups here and abroad. Patients and society will suffer. [br] The word "streamline" in Paragraph 2 probably means______.
选项
A、strengthen
B、simplify
C、ascertain
D、subvert
答案
B
解析
语义题。根据题干定位到原文第二段首句。其中cumbersome表示“讨厌的,麻烦的,笨重的”。既然原来的过程是很繁琐的,那需要做的就是简化这一过程。故答案为B。
转载请注明原文地址:http://tihaiku.com/zcyy/4031386.html
相关试题推荐
TheFederalGovernment______farmersbybuyingtheirsurpluscropsatpricesabov
NowtheythinkthattheirviewsaboutthepresidentandhispoliciesonIraq,gl
AnyDemocraticpresidentwilltryto_____theUnitedStatesfromthemessinIraq
In1784,fiveyearsbeforehebecamepresidentoftheUnitedStates,GeorgeWa
In1784,fiveyearsbeforehebecamepresidentoftheUnitedStates,GeorgeWa
In1784,fiveyearsbeforehebecamepresidentoftheUnitedStates,GeorgeWa
GeorgeMasonmustrankwithJohnAdamsandJamesMadisonasoneofthethree
Thepresidentofthecollege,togetherwiththedeans,____aconferenceforthep
AlongtimeaidetoPresidentBushwhowroteoccasionalguestcolumnsforhis
AlongtimeaidetoPresidentBushwhowroteoccasionalguestcolumnsforhis
随机试题
Iwillhavebeguntodothework______5o’clockthisafternoon.A、byB、atC、afte
膳食纤维属于( )。A.纤维素 B.非淀粉多糖 C.半纤维素 D.粗纤维
糖尿病患者的糖化血红蛋白实验(HbAlc)结果超过下述哪一项数值时,牙周洁刮治后
甲公司以一项长期股权投资与乙公司交换一台设备和一项无形资产,甲公司的长期股权投资
流行性出血热的病毒传播途径不包括( )。A.夏天蚊虫叮咬患者,然后再叮咬其他人
有明确目标、问题和范围,有详细的观察计划、步骤和合理设计的可控制性的观察是()
下列哪种疾病的肝体积不缩小? A.门脉性肝硬化早期B.坏死后性肝硬化
( )是商业银行资本总额与风险加权资产的比值,反映的是一家银行的整体资本稳健水
(2019年真题)根据保险法律制度的规定,下列关于保险经纪人的表述中,正确的是(
女,30岁。妊娠35周,发现血压升高3周。今晨突然腹痛,呈持续性,阴道有少量流血
最新回复
(
0
)